Data Support Moving Forward With Further Development in
Alzheimer’s Disease Psychosis
Conference Call and Webcast to Be Held Today, December 20, 2016,
at 8:30 a.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Dec. 20, 2016--
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced positive
top-line results from its Phase II exploratory study (-019 Study) of
pimavanserin in patients with Alzheimer’s disease psychosis (AD
Psychosis). As a selective serotonin inverse agonist (SSIA)
preferentially targeting 5-HT2A receptors, pimavanserin has a
different biological mechanism than other marketed antipsychotics.
Pimavanserin has been approved by the United States Food and Drug
Administration (FDA) for hallucinations and delusions associated with
Parkinson’s disease psychosis and currently is being studied in several
other disease states, including AD Psychosis. The FDA has not approved
any drug to treat AD Psychosis.
In this Phase II exploratory study, pimavanserin met the primary
endpoint showing a statistically significant reduction in psychosis
versus placebo as measured by the Neuropsychiatric Inventory-Nursing
Home (NPI-NH) Psychosis score at week 6 of dosing (p=0.0451).
Pimavanserin was generally well tolerated and the safety profile was
consistent with what has been observed in previous studies.
“Alzheimer’s disease patients suffer from a number of debilitating
symptoms, of which psychosis carries a poor prognosis and is associated
with earlier placement into nursing homes,” said Steve Davis, ACADIA’s
President and Chief Executive Officer. “Data from the -019 Study provide
solid evidence that pimavanserin can improve psychosis in another major
neurological disorder and provide strategic momentum for the further
development of pimavanserin to address the needs of AD Psychosis
About the Phase II -019 Study
The Phase II -019 Study was a
double-blind, placebo-controlled exploratory trial designed to evaluate
the efficacy and safety of pimavanserin as a treatment for patients with
AD Psychosis. A total of 181 patients were enrolled in the study in the
United Kingdom and randomized on a one-to-one basis to receive either 34
mg of pimavanserin or placebo once daily. The primary endpoint of the
study was antipsychotic efficacy as measured by the mean change in the
NPI-NH Psychosis score (combined hallucinations and delusions domains)
from baseline to week 6 of dosing. Patients continued dosing through
week 12 to gather information on secondary endpoints, including changes
Pimavanserin demonstrated efficacy on the primary endpoint of the -019
Study with a 3.76 point improvement in psychosis at week 6 compared to a
1.93 point improvement for placebo, representing a statistically
significant treatment improvement in the NPI-NH Psychosis score
(p=0.0451). Baseline mean scores for the pimavanserin and placebo
treated groups were 9.52 and 10.00, respectively.
Atypical antipsychotics have been associated with a statistically
significant worsening of cognitive function in patients with Alzheimer’s
disease. In the -019 Study, over the course of 12 weeks of treatment,
pimavanserin did not impair cognition as measured by the Mini-Mental
State Examination (MMSE) score and was similar to placebo. On the
secondary endpoint of mean change in NPI-NH Psychosis score at week 12,
pimavanserin maintained the improvement on psychosis observed at the
week 6 primary endpoint, but did not statistically separate from placebo.
In the -019 Study, pimavanserin was generally well tolerated and the
safety profile was consistent with what has been observed in previous
studies. Based on a preliminary analysis of safety data, the most common
adverse events reported were falls, urinary tract infection and agitation.
The mortality rate was the same in the pimavanserin and placebo
treatment groups. The mean age of patients in the study was 86 years.
The data analysis of the Phase II -019 Study is ongoing and ACADIA plans
to present data from this study at a future medical conference.
Conference Call and Webcast Information
ACADIA will host a
conference call and webcast today, December 20, 2016 at 8:30 a.m.
Eastern Time to discuss top-line results from its Phase II trial with
pimavanserin in patients with Alzheimer’s disease psychosis. The
conference call can be accessed by dialing 844-821-1109 for participants
in the U.S. and Canada and 830-865-2550 for international callers
(reference passcode 43052480). The conference call will be webcast live
on ACADIA’s website, www.acadia-pharm.com,
under the investors section and will be archived there until January 3,
2017. A telephone replay also may be accessed through January 3, 2017 by
dialing 855-859-2056 for participants in the U.S. and Canada and
404-537-3406 for international callers (reference passcode 43052480).
About Alzheimer’s Disease Psychosis (AD Psychosis)
to the Alzheimer’s Association, around 5.4 million people in the United
States are living with Alzheimer’s disease and approximately half are
diagnosed with the disease. Studies suggest that 25 to 50 percent of
patients diagnosed with Alzheimer’s disease may develop psychosis,
commonly consisting of hallucinations and delusions. AD Psychosis is
associated with more rapid cognitive and functional decline, greater
caregiver burden, and earlier institutionalization. The FDA has not
approved any drug to treat AD Psychosis.
Pimavanserin is a selective serotonin
inverse agonist (SSIA) preferentially targeting 5-HT2A
receptors. These receptors are thought to play an important role in AD
Psychosis. Pimavanserin is being evaluated in an extensive clinical
development program by ACADIA across multiple other indications
including Alzheimer’s disease agitation, schizophrenia – inadequate
response, schizophrenia – negative symptoms, and major depressive
disorder. Pimavanserin (34 mg) was approved for the treatment of
hallucinations and delusions associated with Parkinson’s disease
psychosis by the FDA in April 2016 under the trade name NUPLAZID®.
NUPLAZID is not approved for patients with AD Psychosis.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical
company focused on the development and commercialization of innovative
medicines to address unmet medical needs in central nervous system
disorders. ACADIA maintains a website at www.acadia-pharm.com
to which we regularly post copies of our press releases as well as
additional information and through which interested parties can
subscribe to receive e-mail alerts.
Statements in this press release
that are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to statements
related to the progress and timing of ACADIA’s drug discovery and
development programs; the benefits to be derived from NUPLAZID
(pimavanserin) and ACADIA’s product candidates, including whether
pimavanserin can improve psychosis in another major neurological
disorder or be used to treat AD Psychosis; whether the data from the
-019 Study support moving forward with further development in AD
Psychosis or provide strategic momentum for the further development of
pimavanserin to address the needs of AD Psychosis patients; and ACADIA’s
plans to present data from the -019 Study. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Actual events or results may differ
materially from those projected in any of such statements due to various
factors, including the risks and uncertainties inherent in drug
discovery, development, approval and commercialization, and in
collaborations with others, and the fact that past results of clinical
trials may not be indicative of future trial results. For a discussion
of these and other factors, please refer to ACADIA’s annual report on
Form 10-K for the year ended December 31, 2015 as well as ACADIA’s
subsequent filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
Important Safety Information and Indication for
NUPLAZID (pimavanserin) tablets
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
Elderly patients with
dementia-related psychosis treated with antipsychotic drugs are at an
increased risk of death. NUPLAZID is not approved for the treatment of
patients with dementia-related psychosis unrelated to the hallucinations
and delusions associated with Parkinson’s disease psychosis.
NUPLAZID is an atypical antipsychotic indicated for the treatment of
hallucinations and delusions associated with Parkinson’s disease
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of
NUPLAZID should be avoided in patients with known QT prolongation or in
combination with other drugs known to prolong QT interval including
Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain
antipsychotic medications, and certain antibiotics. NUPLAZID should also
be avoided in patients with a history of cardiac arrhythmias, as well as
other circumstances that may increase the risk of the occurrence of
torsade de pointes and/or sudden death, including symptomatic
bradycardia, hypokalemia or hypomagnesemia, and presence of congenital
prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID
and greater than placebo) were peripheral edema (7% vs 2%), nausea (7%
vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%),
constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Strong CYP3A4 inhibitors (eg, ketoconazole) increase
NUPLAZID concentrations. Reduce the NUPLAZID dose by one-half. Strong
CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced
efficacy. Increase in NUPLAZID dosage may be needed.
Renal Impairment: No dosage adjustment for NUPLAZID is needed in
patients with mild to moderate renal impairment. Use of NUPLAZID is not
recommended in patients with severe renal impairment.
Hepatic Impairment: Use of NUPLAZID is not recommended in patients with
hepatic impairment. NUPLAZID has not been evaluated in this patient
Pregnancy: Use of NUPLAZID in pregnant women has not been evaluated and
should therefore be used in pregnancy only if the potential benefit
justifies the potential risk to the mother and fetus.
Pediatric Use: Safety and efficacy have not been established in
Dosage and Administration: Recommended dose: 34 mg per day, taken orally
as two 17-mg tablets once daily, without titration.
For additional Important Safety Information, including boxed warning,
please see the full Prescribing Information for NUPLAZID at https://www.nuplazid.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161220005379/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Jon Shure, (240) 426-4282